Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 27, Issue , 2016, Pages v38-v49

  Smyth, E C ^a   Verheij, M ^b   Allum, W ^a   Cunningham, D ^a   Cervantes, A ^c   Arnold, D ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Instituto CUF de Oncologia   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NIVOLUMAB; OXALIPLATIN; PACLITAXEL; PEMBROLIZUMAB; RAMUCIRUMAB; TRASTUZUMAB; UFT;

ADJUVANT THERAPY; ARTICLE; ASIA; BLOOD ANALYSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; ELDERLY CARE; ENDOSCOPIC SURGERY; EUROPE; FOLLOW UP; GASTRECTOMY; GASTROSCOPY; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY FUNCTION TEST; LAPAROSCOPIC SURGERY; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PERITONEUM METASTASIS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK ASSESSMENT; STOMACH BIOPSY; STOMACH CANCER; STOMACH SURGERY; TREATMENT PLANNING; UNITED STATES;

EID: 84995810855     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw350     Document Type: Article

References (104)

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Arnold M, Karim-Kos HE, Coebergh JW et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015; 51: 1164-1187.
3. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20: 633-649.
4. World Cancer Research Fund International/American Institute for Cancer Research. Continuous update project report: diet, nutrition, physical activity and stomach cancer. 2016. wcrf.org/stomach-cancer-2016 (8 August 2016, date last accessed).
5. Zanghieri G, Di Gregorio C, Sacchetti C et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 1990; 66: 2047-2051.
6. Palli D, Galli M, Caporaso NE et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994; 3: 15-18.
7. van der Post RS, Vogelaar IP, Carneiro F et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52: 361-374.
8. Bass AJ, Thorsson V, Shmulevich I et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209.
9. Ba-Ssalamah A, Prokop M, Uffmann M et al. Dedicated multidetector CT of the stomach: spectrum of diseases. Radiographics 2003; 23: 625-644.
10. Chen CY, Hsu JS, Wu DC et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. Radiology 2007; 242: 472-482.
11. Kim YN, Choi D, Kim SH et al. Gastric cancer staging at isotropic MDCT including coronal and sagittal MPR images: endoscopically diagnosed early vs. advanced gastric cancer. Abdom Imaging 2009; 34: 26-34.
12. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 2009; 12: 6-22.
13. Catalano MF, Sivak MV, Jr, Rice T et al. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc 1994; 40: 442-446.
14. Bhutani MS, Hawes RH, Hoffman BJ. A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion. Gastrointest Endosc 1997; 45: 474-479.
15. Leake PA, Cardoso R, Seevaratnam R et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012; 15 (Suppl. 1): S27-S37.
16. Leake PA, Cardoso R, Seevaratnam R et al. A systematic review of the accuracy and indications for diagnostic laparoscopy before curative-intent resection of gastric cancer. Gastric Cancer 2012; 15 (Suppl. 1): S38-S47.
17. Sobin LH, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours, 7th edition. Oxford, UK: Wiley-Blackwell 2009.
18. Edge SB, Byrd DR, Compton CC (eds). AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer 2010.
19. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2015; 47: 829-854.
20. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123.
21. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
22. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79: 1522-1530.
23. Degiuli M, Sasako M, Ponti A et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014; 101: 23-31.
24. Songun I, Putter H, Kranenbarg EM et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
25. Dikken JL, van Sandick JW, Allum WH et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013; 100: 83-94.
26. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-1751.
27. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
28. National Oesophago-Gastric Cancer Audit 2015. Healthcare Quality Improvement Partnership Ltd, 2015. http://www.hqip.org.uk/resources/national-oesophago-gastric-cancer-audit-report-2015/ (8 August 2016, date last accessed).
29. Mortensen K, Nilsson M, Slim K et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS(r)) Society recommendations. Br J Surg 2014; 101: 1209-1229.
30. Quan Y, Huang A, Ye M et al. Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis. Gastric Cancer 2016; 19: 939-950.
31. Lee JH, Nam BH, Ryu KW et al. Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg 2015; 102: 1500-1505.
32. Kim W, Kim HH, Han SU et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg 2016; 263: 28-35.
33. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
34. Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721.
35. Schuhmacher C, Gretschel S, Lordick F et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218.
36. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
37. Alderson D, Langley RE, Nankivell MG et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol 2015; 33 (Suppl): abstr 4002.
38. Pauligk C, Tannapfel A, Meiler J et al. 36LBA: Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/ esophagogastric junction (EGJ) cancer: data from the phase II part of the FLOT4 phase III study of the AIO. Eur J Cancer 2015; 51(Suppl. S3): 756.
39. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
40. Smalley SR, Benedetti JK, Haller DG et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333.
41. Dikken JL, Jansen EP, Cats A et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010; 28: 2430-2436.
42. Kim S, Lim DH, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.
43. Lee J, Lim DH, Kim S et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273.
44. Zhu WG, Xua DF, Pu J et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012; 104: 361-366.
45. Park SH, Sohn TS, Lee J et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the Adjuvant Chemoradiotherapy in Stomach Tumors trial, including survival and subset analyses. J Clin Oncol 2015; 33: 3130-3136.
46. Stiekema J, Trip AK, Jansen EP et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol 2014; 21: 1107-1114.
47. Trip AK, Nijkamp J, van Tinteren H et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiother Oncol 2014; 112: 289-294.
48. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
49. Sasako M, Sakuramoto S, Katai H et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393.
50. Bang YJ, Kim YW, Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321.
51. Noh SH, Park SR, Yang HK et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 1389-1396.
52. Tsuburaya A, Yoshida K, Kobayashi M et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014; 15: 886-893.
53. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
54. Verheij M, Jansen EPM, Cats A et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study. J Clin Oncol 2016; 34 (Suppl): abstr 4000.
55. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; 3: CD004064.
56. Glimelius B, Ekström K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
57. Bouché O, Raoul JL, Bonnetain F et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study- FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
58. Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534.
59. Starling N, Rao S, Cunningham D et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
60. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457.
61. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
62. Shah MA, Janjigian YY, Stoller R et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol 2015; 33: 3874-3879.
63. Al-Batran SE, Hartmann JT, Hofheinz R et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19: 1882-1887.
64. Van Cutsem E, Boni C, Tabernero J et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 2015; 26: 149-156.
65. Guimbaud R, Louvet C, Ries P et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. J Clin Oncol 2014; 32: 3520-3526.
66. Xiang XJ, Zhang L, Qiu F et al. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy 2012; 58: 1-7.
67. Lee JL, Kang YK, Kang HJ et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99: 584-590.
68. Catalano V, Bisonni R, Graziano F et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer 2013; 16: 411-419.
69. Rivera F, Massutí B, Salcedo M et al. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in 'suboptimal' patients with advanced gastric cancer (AGC). TTD 08-02. Cancer Chemother Pharmacol 2015; 75: 319-324.
70. Trumper M, Ross PJ, Cunningham D et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006; 42: 827-834.
71. Al-Batran SE, Pauligk C, Homann N et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65 +). Eur J Cancer 2013; 49: 835-842.
72. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
73. Ford HE, Marshall A, Bridgewater JA et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78-86.
74. Kang JH, Lee SI, Lim DH et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
75. Roy AC, Park SR, Cunningham D et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013; 24: 1567-1573.
76. Hironaka S, Ueda S, Yasui H et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31: 4438-4444.
77. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235.
78. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
79. Okines AF, Asghar U, Cunningham D et al. Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer. Oncology 2010; 79: 150-158.
80. Tey J, Back MF, Shakespeare TP et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007; 67: 385-388.
81. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
82. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489.
83. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499.
84. Cunningham D, Tebbutt NC, Davidenko I et al. Phase III, randomized, doubleblind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33 (Suppl): abstr 4000.
85. Shah MA, Bang YJ, Lordick F et al. METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol 2015; 33 (Suppl): abstr 4012.
86. Le DT, Bendell JC, Calvo E et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/ GEC): results from the CheckMate-032 study. J Clin Oncol 2016; 34 (Suppl 45): abstr 6.
87. Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717-726.
88. Markar SR, Mackenzie H, Mikhail S et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer 2016. [Epub ahead of print].
89. Shiono S, Sato T, Horio H et al. Outcomes and prognostic factors of survival after pulmonary resection for metastatic gastric cancer. Eur J Cardiothorac Surg 2013; 43: e13-e16.
90. Rosa F, Marrelli D, Morgagni P et al. Krukenberg tumors of gastric origin: the Rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 2016; 40: 921-928.
91. Fujitani K, Yang HK, Mizusawa J et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17: 309-318.
92. Fujimoto S, Takahashi M, Mutou T et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534.
93. Fujimura T, Yonemura Y, Muraoka K et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994; 18: 150-155.
94. Yang XJ, Huang CQ, Suo T et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575-1581.
95. Glehen O, Gilly FN, Arvieux C et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010; 17: 2370-2377.
96. Heger U, Blank S, Wiecha C et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol 2014; 21: 1739-1748.
97. Charalampakis N, Nogueras González GM, Elimova E et al. The proportion of signet ring cell component in patients with localized gastric adenocarcinoma correlates with the degree of response to pre-operative chemoradiation. Oncology 2016; 90: 239-247.
98. Allum WH, Blazeby JM, Griffin SM et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472.
99. D'Ugo D, Biondi A, Tufo A, Persiani R. Follow-up: the evidence. Dig Surg 2013; 30: 159-168.
100. Baiocchi GL, D'Ugo D, Coit D et al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer 2016; 19: 15-20.
101. Hu Y, Kim HI, Hyung WJ et al. Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors. Ann Surg 2013; 258: 970-975.
102. Baek KH, Jeon HM, Lee SS et al. Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients. Bone 2008; 42: 61-67.
103. Verschuur EM, Steyerberg EW, Tilanus HW et al. Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. Br J Cancer 2009; 100: 70-76.
104. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.